An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol…
More: continued here
Filed under: Liver Disease / Hepatitis on February 6th, 2012 | No Comments »
Caffeine consumption has long been associated with decreased risk of liver disease and reduced fibrosis in patients with chronic liver disease. Now, newly published research confirms that coffee caffeine consumption reduces the risk of advanced fibrosis in those with nonalcoholic fatty liver disease (NAFLD)…
More: continued here
Filed under: Liver Disease / Hepatitis on February 6th, 2012 | No Comments »
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic variations produce these different responses by investigating liver cells from different individuals in […]
Filed under: Liver Disease / Hepatitis on February 4th, 2012 | No Comments »
Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. Scientists believe that if they could study liver cells from different people in the lab, they could determine how […]
Filed under: Liver Disease / Hepatitis on February 3rd, 2012 | No Comments »
Researchers from the U.K. determined that preoperative cardiopulmonary exercise testing (CPET) is a specific predictor of 90-day survival following liver transplantation…
More: continued here
Filed under: Liver Disease / Hepatitis on February 1st, 2012 | No Comments »
A study in the January 18 issue of JAMA reveals that the majority of children who received liver transplant grafts from a parent were able to stay off immunosuppression therapy for at least 1 year with normal graft function after gradual withdrawal from the therapy…
More: continued here
Filed under: Liver Disease / Hepatitis on January 23rd, 2012 | No Comments »
Research from the University of Michigan Health System shows the risk for kidney failure among liver transplant recipients is higher following the implementation of Model of End Stage Liver Disease (MELD), a policy change in 2002 that altered how liver transplant allocation is decided. The study, led by Pratima Sharma, M.D., M.S…
More: continued here […]
Filed under: Liver Disease / Hepatitis on January 23rd, 2012 | No Comments »
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist. The study, which was published Jan…
More: continued here
Filed under: Liver Disease / Hepatitis on January 23rd, 2012 | No Comments »
Researchers at the University of British Columbia have found a new way to block infection from the hepatitis C virus (HCV) in the liver that could lead to new therapies for those affected by this and other infectious diseases. More than 170 million people worldwide suffer from hepatitis C, the disease caused by chronic HCV […]
Filed under: Liver Disease / Hepatitis on January 17th, 2012 | No Comments »
Massachusetts General Hospital (MGH) investigators have developed a novel strategy to protect the liver from drug-induced injury and improve associated drug safety…
More: continued here
Filed under: Liver Disease / Hepatitis on January 17th, 2012 | No Comments »